Carperitide
Recombinant human atrial natriuretic peptide (α-hANP)
28 Amino Acids · MW: ≈3,080 Da
Amino Acids
28
Molecular Weight
≈3,080 Da
Half-life
≈2–5 minutes
Research Score
4.6
Studies
180
Storage
Store lyophilized at -20°C, reconstituted at 2-8°C
What is Carperitide?
Recombinant human atrial natriuretic peptide used mainly in acute heart failure and perioperative volume overload. It promotes natriuresis, vasodilation, and suppression of RAAS signaling to lower preload and afterload.
Key Benefits & Mechanisms
natriuresis
vasodilation
preload reduction
renal perfusion support
Research Summary
Carperitide has been studied extensively in Japan and in translational heart-failure models. Data support short-term hemodynamic improvement and renal natriuresis, though mortality benefit remains uncertain.
Related Peptides
Nesiritide
Recombinant human B-type natriuretic peptide (BNP-32)
Synthetic BNP used to counteract fluid overload and elevated cardiac filling pressures. It increases cyclic GMP, causing venous and arterial vasodilation plus natriuresis.
CardiovascularUlaritide
Synthetic human urodilatin
Urodilatin is a renal natriuretic peptide derived from the proANP precursor and studied as an IV heart-failure therapy. It produces strong natriuresis and vasodilation with a relatively rapid onset.
CardiovascularCenderitide
CD-NP chimeric natriuretic peptide
Cenderitide is a designer natriuretic peptide combining features of CNP and dendroaspis natriuretic peptide. It was engineered to provide balanced natriuretic and vasodilatory activity with potential renal-sparing effects.
CardiovascularCNP
Human C-type natriuretic peptide (CNP-22)
CNP is an endogenous natriuretic peptide that signals through NPR-B and increases cGMP. In cardiovascular research it is studied for vasoprotective, anti-fibrotic, and endothelial-supportive actions.
Cardiovascular